Does Medicare Cover Wegovy?
Updated October 2026 · 2026 figures from CMS and Medicare.gov
Partly. By law, Part D plans can't cover Wegovy for weight loss alone, but they can cover it to cut heart attack and stroke risk in people with heart disease, or for MASH liver disease. For weight loss, the separate Medicare GLP-1 Bridge charges $50 a month from July 1, 2026 to December 31, 2027 if you meet its BMI rules.
Jump to: which route applies to you · the $50 Bridge rules · 2026 and 2027 prices · if you're denied
Does Medicare cover Wegovy for you? Find your route
Does Medicare cover Wegovy in your case? It depends on why the drug is prescribed. Find your situation below; it decides whether you go through the Bridge, your drug plan, or neither.
| Why it's prescribed | Drug | Who pays | Your cost |
|---|---|---|---|
| Weight loss, and you meet the Bridge BMI rules | Wegovy (shot or pill), Foundayo, Zepbound KwikPen | Medicare GLP-1 Bridge | $50 a month |
| Lower heart attack and stroke risk, with heart disease and overweight | Wegovy | Your Part D plan, if on its formulary | Plan copay, up to the $2,100 cap |
| MASH liver disease (not cirrhosis) | Wegovy | Your Part D plan | Plan copay |
| Type 2 diabetes | Ozempic, Rybelsus, Mounjaro | Your Part D plan | Plan copay |
| Moderate-to-severe sleep apnea with obesity | Zepbound | Your Part D plan | Plan copay |
| Weight loss, but you don't meet the BMI rules | Any | Not covered | Self-pay price |
If a use is covered under your plan, you aren't eligible for the Bridge: CMS routes prescriptions for diabetes, sleep apnea, MASH and heart risk reduction to Part D plans. Sources: CMS, Medicare GLP-1 Bridge information for providers; KFF, May 2026.
Does Medicare cover Wegovy for weight loss?
Not under Part D: federal law bars Medicare drug plans from covering drugs used only for weight loss. The Medicare GLP-1 Bridge is a temporary CMS demonstration that works around that ban by paying for these drugs outside your Part D plan.
Medicare pays a negotiated price of $245 a month for each Bridge drug; you pay $50 and Medicare pays the other $195. About 500,000 people enrolled in the first two months, according to the White House, as reported by AARP in September 2026.
The Medicare GLP-1 Bridge: who qualifies
You qualify if you have eligible Medicare drug coverage, are 18 or older, are prescribed the drug for weight loss and meet one of three BMI groups when you started the drug. Most people with Part D are in an eligible plan.
| BMI when you started the drug | Plus one of these conditions |
|---|---|
| 35 or higher | None needed |
| 30 or higher | Heart failure with preserved ejection fraction, high blood pressure that's uncontrolled despite two medicines, or chronic kidney disease stage 3a or worse |
| 27 or higher | Prediabetes, a past heart attack, a past stroke, or symptomatic peripheral artery disease |
- Excluded: people with type 2 diabetes, moderate-to-severe sleep apnea or MASH, who get GLP-1s through their Part D plan instead.
- Plans: stand-alone drug plans and most Medicare Advantage plans with drug coverage, including special needs plans and employer group plans. Private fee-for-service, cost, PACE and some other plan types qualify only with a separate stand-alone drug plan.
- Dual eligibles: people with both Medicare and Medicaid in an eligible plan can use it.
- Drugs: Wegovy (all doses, shot and tablets), Foundayo tablets and the Zepbound KwikPen. Zepbound vials and single-dose pens, and pen needles, aren't covered.
- Already taking a GLP-1? You can qualify if your BMI met the rules when you started.
Sources: CMS prescriber summary, June 2026; NPR.
Covered uses under your drug plan: heart, liver, diabetes and sleep apnea
Your regular drug plan can pay for Wegovy when it's prescribed for an FDA-approved use other than weight loss; Part D plans can cover GLP-1 drugs for any such use. Wegovy is approved to reduce the risk of major cardiovascular events in adults with established heart disease and obesity or overweight, and for MASH; Ozempic and Rybelsus treat type 2 diabetes.
- Formulary: each plan decides whether Wegovy is on its drug list. Check with the Medicare Plan Finder before you pick a plan.
- Prior authorization: expect your plan to ask your doctor to confirm the diagnosis, such as a past heart attack or stroke.
- Cap: your costs for covered drugs stop at $2,100 in 2026 and $2,400 in 2027; see how the Part D cap and deductible work.
Novo Nordisk confirms Wegovy remains available under normal Part D benefits for its heart indication: Novo Nordisk, May 2026.
What you'll pay in 2026 and 2027
Does Medicare cover Wegovy at a lower price in 2027? For covered uses in Part D, yes. Prices change because Medicare's first negotiated price for semaglutide, the ingredient in Wegovy, Ozempic and Rybelsus, takes effect on January 1, 2027. It's $274 for a month's supply, 71% below the 2024 list price of $959.
| Item | 2026 | 2027 |
|---|---|---|
| Bridge copay (weight loss) | $50 a month (from July 1) | $50 a month (through Dec. 31) |
| Medicare's price for Bridge drugs | $245 a month | $245 a month |
| Medicare-negotiated semaglutide price (covered uses in Part D) | Not yet in effect | $274 a month |
| Wegovy 2.4 mg, 4 pens, negotiated price | Not yet in effect | $385.63 |
| Ozempic 4 mg pen or 30 Rybelsus 7 mg tablets, negotiated price | Not yet in effect | $276.78 |
| Part D out-of-pocket cap | $2,100 | $2,400 |
| Maximum Part D deductible | $615 | $700 |
Example for 2027: if your plan charges 25% coinsurance on Ozempic after the deductible, 25% of $276.78 is about $69 a month. Plans set their own copays, so check your plan's 2027 drug list during open enrollment. The negotiated prices and the $245 Bridge price come from separate agreements. Sources: AMCP summary of CMS 2027 negotiated prices; Managed Healthcare Executive.
How to get Wegovy through the Bridge, step by step
Start with your prescriber, not your drug plan: the Bridge is run by a CMS contractor, and your plan isn't part of the approval.
- Check your plan: you need a stand-alone Part D plan or a Medicare Advantage plan with drug coverage (private fee-for-service, cost and PACE plans need a separate Part D plan).
- Check the medical rules with your prescriber: age 18 or older, no type 2 diabetes, moderate-to-severe sleep apnea or MASH, and one of the three BMI groups, measured when you started the drug.
- Ask your prescriber to send the prescription marked "SEND TO BRIDGE FOR WEIGHT MANAGEMENT" with an obesity diagnosis code. The prescriber doesn't need to be enrolled in Medicare.
- Fill it at your pharmacy. The first claim triggers a prior authorization request; CMS aims to decide within 72 hours and mails you the decision.
- Once approved, pay $50 for each 28- or 30-day supply. Refills don't need a new approval unless you switch drugs.
- If you're denied, ask your prescriber to correct or add information and resubmit; there is no formal appeal.
Questions about drug coverage go to 1-800-633-4227 (TTY 1-877-486-2048); prescribers can call the Bridge call center at 855-273-0102. More numbers are on our Medicare phone number guide.
If you're denied or don't qualify
There's no formal appeal for the Bridge, but other routes exist. Which one fits depends on why you were turned down.
- Bridge denial: your prescriber can correct the form or add new information and resubmit.
- Part D denial for a covered use: ask your plan for a coverage determination or a formulary exception, then a redetermination within 65 days. Your doctor's supporting statement matters most.
- Medicaid: 13 states covered GLP-1s for obesity as of January 2026, according to KFF. If you have both programs, ask your state Medicaid office; see how Medicare and Medicaid work together.
- Self-pay: in May 2026, NPR reported self-pay prices on TrumpRx.gov of $199 to $399 a month for Wegovy injections and up to $299 for Wegovy tablets. Copay cards can't be used with Medicare coverage.
- Change plans: if your plan doesn't list Wegovy for heart risk, compare plans during open enrollment, October 15 to December 7.
Retirement Rules Guide is independent and can't see your plan or prescriptions. Whether a GLP-1 is right for you is a medical decision; many people regain weight after stopping these drugs, so talk with your doctor about long-term plans.
Where that leaves you: for weight loss, Wegovy costs $50 a month through 2027 if you qualify for the Bridge; for heart risk or MASH, your drug plan can cover it. Related coverage guides: dental care, cataract surgery and Medicare Advantage plans.
Frequently asked questions
Does Medicare cover Wegovy for weight loss in 2026?
Yes, through the Medicare GLP-1 Bridge, not your Part D plan. Since July 1, 2026, eligible people with Part D pay $50 a month for Wegovy injections or tablets used for weight loss, after their prescriber gets prior authorization. You need a BMI of 35 or more, or 27 or 30 or more with certain conditions.
Does Medicare cover Ozempic for weight loss?
No. Ozempic is covered under Part D for type 2 diabetes, at your plan's copay, but not for weight loss, and it isn't one of the Bridge drugs. For weight loss, the Bridge covers Wegovy, Foundayo and the Zepbound KwikPen. People with type 2 diabetes are excluded from the Bridge.
Does the $50 Bridge copay count toward the Part D out-of-pocket cap?
No. The Bridge runs outside Part D, so its $50 copays don't count toward your Part D deductible or the $2,100 cap in 2026. Extra Help doesn't lower them, and they can't be spread through the Medicare Prescription Payment Plan.
Does Medicare cover Wegovy if I'm on Medicare Advantage?
Yes, if your plan includes drug coverage. Members of most Medicare Advantage plans with drug coverage can use the Bridge for weight loss, and the plan's drug benefit can cover Wegovy for heart risk or MASH. Private fee-for-service, cost and PACE plan members need a separate drug plan to use the Bridge.
What happens to the $50 price after 2027?
No one knows yet. The Bridge is scheduled to end December 31, 2027. CMS postponed indefinitely the longer-term BALANCE model for Medicare after too few drug plans applied, and it will use Bridge data to decide what comes next. Watch for announcements before open enrollment in fall 2027.
Can I appeal if the Bridge denies Wegovy?
Not formally. The Bridge has no appeals process; your prescriber can fix the information and resubmit the prior authorization request. If your Part D plan denies Wegovy for a covered use, such as heart risk reduction, you can ask for an exception and then a redetermination within 65 days.
Does Medicare cover Wegovy pills as well as shots?
Yes. The Bridge covers Wegovy tablets and injections, in all doses, for the same $50 a month. For the Bridge, a month means one box of 4 pens or one bottle of 30 tablets, filled as a 28- or 30-day supply. The $50 doesn't go up when your dose increases.
Can I use a Wegovy savings card with Medicare?
No. Manufacturer copay cards can't be used with Medicare drug coverage. You can instead pay the maker's self-pay price outside your plan, which in 2026 ranges from $199 to $399 a month for the injection, but that spending won't count toward your Part D cap.